Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EVALUATION OF PYRAZOLOACRIDINE IN PATIENTS WITH ADVANCED PANCREATIC-CARCINOMA
Autore:
ZALUPSKI MM; SHIELDS AF; PHILIP PA; KRAUT M; LORUSSO P; HEILBRUN LK; VAITKEVICIUS V;
Indirizzi:
WAYNE STATE UNIV,KARMANOS CANC INST,DIV HEMATOL & ONCOL,POB 02188 DETROIT MI 48201
Titolo Testata:
Investigational new drugs
fascicolo: 1, volume: 16, anno: 1998,
pagine: 93 - 96
SICI:
0167-6997(1998)16:1<93:EOPIPW>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
SOLID TUMORS; PHASE-II; CANCER; 5-FLUOROURACIL; SURVIVAL; THERAPY; TRIAL; AGENT;
Keywords:
PYRAZOLOACRIDINE; PZA; PANCREATIC CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
17
Recensione:
Indirizzi per estratti:
Citazione:
M.M. Zalupski et al., "EVALUATION OF PYRAZOLOACRIDINE IN PATIENTS WITH ADVANCED PANCREATIC-CARCINOMA", Investigational new drugs, 16(1), 1998, pp. 93-96

Abstract

Purpose: Pyrazoloacridine (PZA) is an acridine derivative selected for clinical development because of broad preclinical antitumor activityand solid tumor selectivity. Phase I evaluations with PZA have demonstrated predictable toxicity and suggested clinical efficacy. A phase Il trial in patients with previously untreated advanced pancreatic cancer was conducted. Methods: PZA was administered at a dose of 750 mg/m(2) intravenously over 3 hours every 21 days. Seventeen patients were treated receiving a total of 46 courses of PZA. Results: Of the 15 patients evaluable for response, no responses were observed (0% response rate, 95% confidence interval 0-22%). Major toxicities directly attributable to PZA included moderate neutropenia and mild neurotoxicity. Conclusion: PZA at this dose and schedule of administration was inactive in patients with pancreatic carcinoma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/10/20 alle ore 02:28:28